HanchorBio Inc.
SAN FRANCISCO, CA and TAIPEI, TAIWAN / ACCESSWIRE / October 3, 2023 / HanchorBio Inc., a global clinical-stage biotechnology company focusing on the discovery and development of innovative immuno-biomedicines to treat a wide variety of patients suffering from different solid tumors or hematological malignancies with significant unmet medical needs, today announced that the first patient has been dosed in a Phase 1, multi-regional, multi-center clinical trial (ClinicalTrials.gov ID: NCT05892718). The trial aims to evaluate the safety, tolerability, pharmacodynamics, and anti-tumor activity of HCB101 in patients with advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma.
"The dosing of the first patient with HCB101 marks another major milestone in evaluating the potential benefit of HCB101 for these patient populations," said Scott Liu, Ph.D., Founder, Chairman, and Chief Executive Officer of HanchorBio. "Based on the preclinical head-to-head comparison studies, HCB101 repeatedly demonstrated superior efficacy and excellent safety profiles in comparison with several similar biologics currently being investigated in clinical trials targeting the same SIRPα-CD47 pathway. I am immensely proud of the teamwork that has brought our differentiated program to this point with only 2.6 years from the Company's inception to IND and now first-patient-in. HanchorBio is dedicated to discovering and developing immunotherapies to overcome the inadequacies of PD-1/L1 therapies with our proprietary FBDB™ technology platform."
"There is an urgent need for new treatment options for patients with cancer, particularly those who cannot tolerate currently available therapies," commented Jason Tsai, M.D., M.S., Chief Medical Officer of HanchorBio. "Through blockade of the SIRPα-CD47 pathway, HCB101 brings additional armament to fight cancer. Our goal is to bring transformative treatment options for patients with cancer by developing HCB101 as a foundational innate immunity checkpoint immunotherapy and open the door to innate-adaptive combination immuno-oncology therapy."
HCB101 is an engineered fusion protein using the Company's proprietary Fc-based designer biologics (FBDB™) technology platform that blocks the "do not eat" signal from the SIRPα-CD47 pathway, which inhibits the ability of macrophages to engulf and destroy cancer cells. Preclinical studies have shown that HCB101 has anti-tumor activity across a wide range of solid tumors and hematological malignancies. Unlike other similar agents, HCB101 exhibits excellent safety profiles in the repeat-dose cynomolgus monkey toxicology studies, as no abnormality of RBC or platelet levels were observed, with a potential as the best-in-class anti-SIRPα-CD47 immunotherapy.
HanchorBio owns worldwide commercial rights to HCB101.
About HCB101
Discovered through a structure-guided protein design and engineering supplemented with relevant screening technologies, HCB101 is an engineered extracellular domain of SIRPα fused to the Fc region of IgG4. HCB101 triggers potent phagocytic activity of the macrophages by primarily blocking the "do not eat" signal between macrophages and tumor cells. Based on the extensive in-vitro and in-vivo preclinical data, HCB101 is potentially a safer and more potent biologic than the anti-CD47 monoclonal antibodies and SIRPa fusion proteins currently being investigated in clinical trials. Furthermore, quantitative RNA transcriptional analysis indicated that HCB101 triggered distinct gene expression profiles inside the tumor and in the tumor microenvironment compared to other relevant clinical candidates, suggesting that HCB101 might exhibit unique mechanisms of action. Using HCB101 as the foundation, our pipeline includes other arms targeting both adaptive and innate immunity to help revolutionize the treatment of patients with cancer and other debilitating diseases.
About Multi-Regional Clinical Trial of HCB101 (NCT05892718)
HCB101-101 is a multi-regional, multi-center, open-label, dose-finding, first-in-human (FIH) study of adults with advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma in the United States and Taiwan. The purposes of the study are to evaluate the safety, tolerability, pharmacokinetics, and clinical anti-tumor activity of HCB101 via intravenous injections. HCB101-101 has already received IND clearance by the U.S. FDA in April 2023 and the Taiwan FDA in July 2023.
About HanchorBio
Based in Taipei, Shanghai, and San Francisco Bay Area, HanchorBio is a global clinical-stage biotechnology company focusing on immuno-oncology. The Company is led by an experienced team of pharmaceutical industry veterans with a proven track record of success in biologics discovery and global development to transcend current cancer therapies. Committed to reactivating the immune system to fight against diseases, the proprietary Fc-based designer biologics (FBDB™) platform enables unique biologics with diverse multi-targeting modalities to unleash both innate and adaptive immunity to overcome the current inadequacies of anti-PD1/L1 immunotherapies. The FBDB™ platform has successfully delivered proof-of-concept data in several in vivo tumor animal models. By making breakthroughs in multi-functional innovative molecular configurations in R&D and improving the manufacturing process in CMC, HanchorBio develops transformative medicines to address unmet medical needs.
For more information, please visit: www.HanchorBio.com or follow us on LinkedIn at www.linkedin.com/company/hanchorbio-inc
Contact Information
Scott Liu
Founder, Chairman and CEO
scott_liu@hanchorbio.com
Yi Du
Sr. Director of Business Development
yi_du@hanchorbio.com
SOURCE: HanchorBio Inc.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/789413/hanchorbio-announces-first-patient-dosed-in-the-phase-1-multi-regional-clinical-trial-of-hcb101
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Nestlé and OMP Showcase Approach to Future-Ready Supply Chain at Gartner Supply Chain Symposium/Xpo in Barcelona9.5.2025 04:20:00 CEST | Press release
BARCELONA, ES / ACCESS Newswire / May 9, 2025 / OMP, a leading provider of supply chain planning solutions, invites attendees of the Gartner Supply Chain Symposium/Xpo™ 2025 to attend Nestlé's solution provider session on May 19. The presentation will highlight how the company is transforming its supply chain across brands and regions using OMP's Unison PlanningTM. In this session, Shannon Novack, Supply Chain Excellence Expert at Nestlé, will share how the global food and beverage leader is reimagining its supply chain planning to meet increasing customer expectations in a fast-changing business environment. By leveraging advanced planning technology like Unison Planning, managing organizational change, and scalingfuture-fit capabilities, Nestlé is delivering real results. Attendees will gain valuable insights into how the company is driving adoption, overcoming transformation challenges, and aligning technology speed with organizational agility. The Gartner Supply Chain Symposium/Xpo
Innodata Reports First Quarter 2025 Results with Revenue up 120% Year-Over-Year and Reaffirms Growth Guidance of 40% or more for 20258.5.2025 16:45:00 CEST | Press release
NEW YORK, NY / ACCESS Newswire / May 8, 2025 / INNODATA INC. (Nasdaq:INOD) today reported results for the first quarter ended March 31, 2025. Revenue of $58.3 million, representing 120% revenue growth year-over-year. Adjusted EBITDA of $12.7 million, an increase of $8.9 million from $3.8 million in the same period last year.* Net income of $7.8 million, or $0.25 per basic share and $0.22 per diluted share, compared to a net income of $1.0 million, or $0.03 per basic and diluted share, in the same period last year. Cash, cash equivalents and short-term investments were $56.6 million as of March 31, 2025 and $46.9 million as of December 31, 2024. * Adjusted EBITDA is defined below. Jack Abuhoff, CEO, said, "We had a strong start to the year. We're being onboarded by potential major new customers, expanding existing relationships, and building a pipeline that's deeper and more advanced than at any point in our history. We are bringing ideas and innovation to our customers that are being w
UK Certifies Protector As First of Its Kind Remotely Piloted Aircraft8.5.2025 12:00:00 CEST | Press release
SAN DIEGO, CALIFORNIA / ACCESS Newswire / May 8, 2025 / The UK's Military Aviation Authority has issued a Military Type Certificate to the Royal Air Force's Protector RG Mk1 uncrewed aircraft, also designated the MQ-9B, certifying that it has passed a rigorous airworthiness assessment and verifying it's safe to operate without geographic restrictions, including over populous areas. This April 29 decision was a first-of-its-kind milestone for a large, unmanned aircraft system. It's a huge accomplishment for the UK and a technological watershed in the history of unmanned aircraft systems. GA-ASI is the first manufacturer of large, unmanned aircraft to receive an MTC based on rigorous compliance with STANAG 4671, the NATO standard for unmanned aircraft system airworthiness. Obtaining the MTC has been a goal of GA-ASI since the inception of the MQ-9B in January 2014. The company took its proven UAS platform, the MQ-9A, and added performance enhancing features while ensuring that the design
The Battery Show Europe 2025 Critical Agenda Highlights Moves to Global Collaboration, Regulation and Supply Chain Resilience8.5.2025 04:00:00 CEST | Press release
Featuring speakers from BMW, CATL, Mercedes Benz, Cellforce and more. STUTTGART, GERMANY / ACCESS Newswire / May 8, 2025 / The Battery Show Europe and Electric & Hybrid Vehicle Technology Expo Europe, co-located with Energy Storage Summit Germany, the region's only dedicated event for battery manufacturing, electric and hybrid vehicle tech industries, has announced its 2025 keynote lineup. The sessions will cover key themes including upcoming supply chain, navigating regulatory and policy changes and staying ahead of the curve on market trends with analysis. "Better Together: Building Resilient Battery Supply Chains Through International Collaboration," opens the program moderated by James Frith, Principal at Volta Energy Technologies, featuring insights from Isobel Sheldon, Global CEO at Western CAM Inc, Ulderico Ulissi, Head of Overseas Tech & Start-up Cooperation at CATL, Jerry Fang, Director of Business Development at Shanghai Putailai New Energy Technology Co., Ltd. and Benoit Lem
Aster Guardians Global Nursing Award Unveils Top 10 Finalists for 2025 from 100,000+ Registrations7.5.2025 10:30:00 CEST | Press release
Over 100,000 registrations received from nurses across 199* countries - a 28% increase from the third edition, which received 78,000+ registrations. One of the shortlisted Top 10 finalists will be honoured with the grand title award and a prize of USD 250,000. These finalists were selected following a rigorous evaluation process, led by esteemed expert jury and grand jury panels. The entire process is independently moderated by the appointed "Process Advisors" Ernst & Young LLP. DUBAI, AE / ACCESS Newswire / May 7, 2025 / Aster DM Healthcare has today announced the Top 10 finalists for the fourth edition of Aster Guardians Global Nursing Award - a prestigious global recognition with USD 250,000 prize money, that honours the exceptional contributions of nurses worldwide. These 10 finalists were selected from a record-breaking pool of 100,000+ registrations across 199* countries, through a stringent evaluation process led by expert jury and Grand jury panels members. The entire process i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom